Title : Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.

Pub. Date : 2019 Apr

PMID : 30936194






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 KRAS G12D-mutant/p53-deficient non-small-cell lung cancer (NSCLC) models are dependent on the NF-kappaB pathway that can be down-regulated by the proteasome inhibitor bortezomib. Bortezomib tumor protein p53 Homo sapiens